| Literature DB >> 28760498 |
Philippe Moingeon1, Laurent Mascarell2.
Abstract
Allergen immunotherapy is the only treatment altering the natural course of IgE-mediated allergies. Whereas the subcutaneous route for immunotherapy (SCIT) has been historically considered as a reference, we discuss herein the relative advantages of the sublingual and oral routes as alternatives to SCIT in order to elicit allergen-specific tolerance. The buccal and gut immune systems are similarly organized to favor immune tolerance to antigens/allergens, due to the presence of tolerogenic dendritic cells and macrophages promoting the differentiation of CD4+ regulatory T cells. Sublingual immunotherapy (SLIT) is now established as a valid treatment option, with clinical efficacy demonstrated in allergic rhinoconjunctivitis (to either grass, tree, weed pollens or mite allergens) and encouraging results obtained in the management of mild/moderate allergic asthma. While still exploratory, oral immunotherapy (OIT) has shown promising results in the desensitization of patients with food allergies. We review at both biological and clinical levels the perspectives currently pursued for those two mucosal routes.Entities:
Keywords: Allergy vaccine; Buccal; Immunotherapy; Oral; Regulatory T cells; Sublingual
Mesh:
Substances:
Year: 2017 PMID: 28760498 DOI: 10.1016/j.smim.2017.07.003
Source DB: PubMed Journal: Semin Immunol ISSN: 1044-5323 Impact factor: 11.130